A Phase 3 interventional study of Levosimendan 2.5 MG/ML Injectable Solution and Placebo in Cardiogenic Shock, sponsored by Pr Bruno LEVY. Recruiting at 28 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-05.
Sponsored by Pr Bruno LEVY · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Shock, Cardiogenic with a site in France — 20 open to participants now, 21 under way, 2 of them phase 3. Shock, Cardiogenic · France.
Among the 62 studies in Shock, Cardiogenic with a site in France, this one has the largest planned enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2023, is one of 6 in phase 3, reaches primary completion later than 10 of the 20 other live ones, and was the 23rd registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →20 of the 62 studies in Shock, Cardiogenic with a site in France are open now. Recruiting first, the newest first:
CMC Ambroise Paré · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
4TEEN4 Pharmaceuticals GmbH · Sites in France, Armenia, Belgium and 6 more countries
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 6 · Phase 4 3
First in 2005; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 610 is above the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.
Median enrollment 164 across the 25 interventional studies, 150 across the 37 observational. Of the 28 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 62 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Pr Bruno LEVY as lead sponsor.
Pr Bruno LEVY has 1 study filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
8 of the studies in Shock, Cardiogenic with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020263Phase 3Pr Bruno LEVYEffect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock | 2027-02-03 |
| NCT05879276Phase 3Central Hospital, Nancy, FranceEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. | 2027-03-16 |
| NCT068327224TEEN4 Pharmaceuticals GmbHA Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. | 2026-12-30 |
| NCT07354568Centre Hospitalier Universitaire, AmiensPrognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock | 2027-01-01 |
| NCT07027202Assistance Publique - Hôpitaux de ParisEarly Preventive Left Ventricle Unloading After VA-ECMO for Refractory Cardiogenic Shock | 2027-07 |
Add all 8 to your calendar (.ics) → With an account.
Among the 62 studies in Shock, Cardiogenic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cardiogenic shock (CS) mortality remains high (40%). Despite their frequent use, few clinical outcome data are available to guide the initial selection of vasoactive drug therapies in patients with CS. Based on experts' opinions, the combination of norepinephrine-dobutamine is generally recommended as a first line strategy. Inotropic agents increase myocardial contractility, thereby increasing cardiac output. Dobutamine is commonly recommended to be the inotropic agent of choice and levosimendan is generally used following dobutamine failure. It may represent an ideal agent in cardiogenic shock, since it improves myocardial contractility without increasing cAMP or calcium concentration. At present, there are no convincing data to support a specific inotropic agent in patients with cardiogenic shock. Our hypothesis is that the early use of levosimendan, by enabling the discontinuation of dobutamine, would accelerate the resolution of signs of low cardiac output and facilitate myocardial recovery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult patient ≥ 18 years with cardiogenic shock defined by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental group: patients with cardiogenic shock treated with levosimendan in addition to the conventional strategy.
Drug: Levosimendan 2.5 MG/ML Injectable Solution
Control group: Patients with cardiogenic shock treated with placebo (Cernevit/Soluvit) in addition to the conventional strategy.
Drug: Placebo
Drug page: SimendanStudies of SimendanSimendan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Levosimendan will be diluted with Glucose G5%. The reconstitution of levosimendan will be performed, as close as possible to the start of the infusion. A continuous infusion of levosimendan will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
Placebo will be diluted with Glucose G5%. The reconstitution of Placebo will be performed, as close as possible to the start of the infusion. A continuous infusion of Placebo will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
Proportion of All-cause mortality
Composite endpoint (i.e. All-cause Mortality and/or Extra Corporel Life Support implantation and/or dialysis)
Time frame: Day 30 following randomization
Proportion of Extra Corporel Life Support implantation
Composite endpoint (i.e. All-cause Mortality and/or Extra Corporel Life Support implantation and/or dialysis)
Time frame: Day 30 following randomization
Proportion of Dialysis
Composite endpoint (i.e. All-cause Mortality and/or Extra Corporel Life Support implantation and/or dialysis)
Time frame: Day 30 following randomization
Time to death
Prioritized composite endpoint with the following priority order: 1/ time to death, 2/ escalation to permanent left ventricular assist device or cardiac transplantation, 3/ dialysis, 4/ ECLS requirement, 5/ number of cardiovascular events (stroke, recurrent myocardial infarction, urgent coronary revascularization, re-hospitalization for heart failure).
Time frame: Day 90
Time to escalation to permanent left ventricular assist device or cardiac transplantation
Prioritized composite endpoint with the following priority order: 1/ time to death, 2/ escalation to permanent left ventricular assist device or cardiac transplantation, 3/ dialysis, 4/ ECLS requirement, 5/ number of cardiovascular events (stroke, recurrent myocardial infarction, urgent coronary revascularization, re-hospitalization for heart failure).
Time frame: Day 90
Time to dialysis
Prioritized composite endpoint with the following priority order: 1/ time to death, 2/ escalation to permanent left ventricular assist device or cardiac transplantation, 3/ dialysis, 4/ ECLS requirement, 5/ number of cardiovascular events (stroke, recurrent myocardial infarction, urgent coronary revascularization, re-hospitalization for heart failure).
Time frame: Day 90
Time to ECLS requirement
Prioritized composite endpoint with the following priority order: 1/ time to death, 2/ escalation to permanent left ventricular assist device or cardiac transplantation, 3/ dialysis, 4/ ECLS requirement, 5/ number of cardiovascular events (stroke, recurrent myocardial infarction, urgent coronary revascularization, re-hospitalization for heart failure).
Time frame: Day 90
number of cardiovascular events
Prioritized composite endpoint with the following priority order: 1/ time to death, 2/ escalation to permanent left ventricular assist device or cardiac transplantation, 3/ dialysis, 4/ ECLS requirement, 5/ number of cardiovascular events (stroke, recurrent myocardial infarction, urgent coronary revascularization, re-hospitalization for heart failure).
Time frame: Day 90
Proportion of death.
Time frame: Day 90
Proportion of Extra Corporel Life Support implantation
Time frame: Day 90
Proportion of dialysis
Time frame: Day 90
Proportion of cardiac transplantation
Time frame: Day 90
Proportion of escalation to permanent Left Ventricular Assist Device
Time frame: Day 90
Proportion of stroke
Time frame: Day 90
Proportion of recurrent myocardial infarction
Time frame: Day 90
Proportion of urgent coronary revascularization
Time frame: Day 90
Proportion of re-hospitalization for heart failure
Time frame: Day 90
Proportion of All-cause mortality
Composite endpoint of all-cause mortality and/or ECLS requirement and/or dialysis on day 90.
Time frame: Day 90
Proportion of Extra Corporel Life Support implantation
Composite endpoint of all-cause mortality and/or ECLS requirement and/or dialysis on day 90.
Time frame: Day 90
Proportion of Dialysis
Composite endpoint of all-cause mortality and/or ECLS requirement and/or dialysis on day 90.
Time frame: Day 90
Number of dobutamine free days
Time frame: From randomization to day 30
Number of vasopressors free days
Time frame: From randomization to day 30
Number of ventilatory free days
Time frame: From randomization to day 30
Number of renal replacement free days
Time frame: From randomization to day 90
Lactate clearance
Time frame: from randomization to day 7
Duration of intensive care unit stay
Time frame: Up to Intensive Care Unit discharge (assessed up to 1 month)
Duration of hospitalization
Time frame: Up to hospitalization discharge (assessed up to 1 month)
Proportion of All-cause mortality
Composite endpoint of all-cause mortality and/or ECLS requirement and/or dialysis
Time frame: days 7, 60, and 180 days and 12 months
Proportion of Extra Corporel Life Support implantation
Composite endpoint of all-cause mortality and/or ECLS requirement and/or dialysis
Time frame: days 7, 60, and 180 days and 12 months
Proportion of dialysis
Composite endpoint of all-cause mortality and/or ECLS requirement and/or dialysis
Time frame: days 7, 60, and 180 days and 12 months
Number of renal replacement free days
Time frame: D 30, 60, 180 and at 12 months
Proportion of death
Time frame: days 180 and at 12 months
Proportion of Extra Corporel Life Support implantation
Time frame: days 180 and at 12 months
Proportion of dialysis
Time frame: days 180 and at 12 months
proportion of cardiac transplantation
Time frame: days 180 and at 12 months
proportion of escalation to permanent left ventricular assist device
Time frame: days 180 and at 12 months
Proportion of stroke
Time frame: days 180 and at 12 months
Proportion of recurrent myocardial infarction
Time frame: days 180 and at 12 months
Proportion urgent coronary revascularization
Time frame: days 180 and at 12 months
proportion of re-hospitalization for heart failure
Time frame: days 180 and at 12 months
Occurrence of arrhythmias requiring therapy
Occurrence of arrhythmias requiring therapy with anti-arrhythmic drugs or electric cardioversion (including atrial fibrillation, ventricular tachycardia, ventricular fibrillation, torsade de pointe)
Time frame: from randomization to intensive care unit discharge.
the changes in biomarkers
From a dedicated biological collection on which we will measure existing and future biological parameters, we will evaluate the effect of Levosimendan on the changes in biomarkers between randomization and ICU/CCU discharge
Time frame: from randomization to intensive care unit discharge.
All-cause mortality and/or ECLS and/or dialysis
From a dedicated biological collection on which we will measure existing and future biological parameters, we will evaluate the ability of clinical and biological measure to predict levosimendan effect for the primary endpoint.
Time frame: Day 30
All-cause mortality and/or ECLS and/or dialysis
From a dedicated biological collection on which we will measure existing and future biological parameters, we will evaluate the ability of biological measure to predict subsequent outcome
Time frame: At intensive care unit discharge
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Feb 2027, 43 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Simendan